For a 69‑year‑old patient with bipolar disorder who is taking caplyta (lumateperone) 10.5 mg daily, which seems like a low dose, is it appropriate to start ketamine therapy for residual depression?

Optimize Caplyta Dosing Before Adding Ketamine for Residual Bipolar Depression

Before considering ketamine therapy, you should first increase the Caplyta dose to the FDA-approved therapeutic level of 42 mg daily, as 10.5 mg is substantially subtherapeutic and represents only 25% of the recommended dose for bipolar depression. 1

Current Dosing Issue

Your patient is on 10.5 mg of lumateperone (Caplyta), which is:

• Far below the FDA-approved dose of 42 mg once daily for bipolar depression 1
• The 10.5 mg strength exists only for dose reduction in hepatic impairment or drug interactions with strong CYP3A4 inhibitors 1
• No dose titration is required—patients can start directly at 42 mg 1

The FDA label explicitly states the recommended dosage is 42 mg once daily for depressive episodes associated with bipolar I or II disorder. 1 Your patient is receiving one-quarter of the therapeutic dose, which explains the residual depression.

Algorithmic Approach

Step 1: Optimize Current Therapy First

• Increase Caplyta to 42 mg daily immediately (unless contraindicated by hepatic impairment or drug interactions)
• Assess response over 4-6 weeks at therapeutic dosing
• Recent meta-analysis confirms lumateperone 42 mg shows statistically significant improvement over placebo on MADRS and CGI-BP-S scores 2

Step 2: If Residual Depression Persists at 42 mg

Only then consider ketamine as adjunctive therapy if:

• Patient has failed at least 2 adequate trials of evidence-based pharmacotherapies (including optimized Caplyta) 3
• This meets criteria for treatment-resistant bipolar depression (TRBD)

Ketamine for Bipolar Depression: Evidence Summary

Ketamine can be effective for treatment-resistant bipolar depression when used adjunctively with mood stabilizers, but it is reserved for patients who have failed multiple adequate trials. 3, 4

Efficacy Data

• Recent 2026 RCT (Ket-BD study): Adjunctive IV ketamine (0.5-0.75 mg/kg) given 4 times over 2 weeks showed significant antidepressant effects vs. midazolam (between-group difference = -7.3 MADRS points; Cohen d = 0.7; p=0.003) 4
• Response rates: 61-80% across studies when ketamine added to mood stabilizers 5, 6
• Systematic review of 135 participants: 61% response rate with ketamine vs. 5% with placebo 5

Safety Considerations in Bipolar Disorder

• Critical requirement: Must continue mood stabilizer or antipsychotic during ketamine treatment 4, 5
• Mania/hypomania risk: 2/135 participants (1.5%) developed manic symptoms across studies 5
• In the 2026 Ket-BD trial: No cases of mania, hypomania, or psychosis observed 4
• Well-tolerated with transient dissociative symptoms 4, 6

Ketamine Protocol if Indicated

• Dosing: 0.5 mg/kg IV over 40 minutes
• Frequency: 2-3 times weekly for 2-4 weeks (4-6 total infusions)
• Setting: Requires certified facility with 2-hour post-treatment monitoring for esketamine; less restrictive for IV ketamine 3
• Continuation: Caplyta 42 mg must be maintained as mood stabilizer

Critical Pitfalls to Avoid

1. Do not add ketamine while patient is on subtherapeutic Caplyta dosing—this bypasses an established, FDA-approved treatment that hasn't been adequately trialed

2. Never use ketamine as monotherapy in bipolar disorder—all evidence supports adjunctive use with mood stabilizers to prevent mood destabilization 4, 5

3. Verify treatment resistance criteria: VA/DoD guidelines specify ketamine is reserved for patients who have failed at least 2 adequate antidepressant trials 3. At 10.5 mg, your patient hasn't had an adequate trial of Caplyta.

4. Age consideration: At 69 years, ensure no contraindications (cardiovascular disease, uncontrolled hypertension) before ketamine, though the 2026 Ket-BD study included patients up to age 65 4

5. Psychiatric comorbidity burden: Higher number of psychiatric comorbidities and benzodiazepine use are associated with ketamine nonresponse 7

Practical Recommendation

Increase Caplyta to 42 mg daily now. Reassess in 4-6 weeks. If depression remains treatment-resistant despite therapeutic dosing of Caplyta (and assuming prior adequate trials of other agents), then ketamine becomes a reasonable adjunctive option with appropriate monitoring and continuation of the mood stabilizer. The 2022 VA/DoD guidelines support this sequential approach, explicitly stating ketamine is "not recommended as initial treatment but reserved for patients for whom previous therapies have failed." 3